NCS-382: Difference between revisions
Jump to navigation
Jump to search
m Protected "NCS-382": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 26: | Line 26: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
'''NCS-382''' is a moderately selective [[Receptor antagonist|antagonist]] for the [[GHB receptor]].<ref>Castelli MP, Pibiri F, Carboni G, Piras AP. A review of pharmacology of NCS-382, a putative antagonist of gamma-hydroxybutyric acid (GHB) receptor. ''CNS Drug Reviews''. 2004 Fall;10(3):243-60. PMID 15492774</ref> It blocks the effects of [[gamma-Hydroxybutyric acid|GHB]] in animals and has both anti-[[sedative]] and [[anticonvulsant]] effects.<ref>Maitre M, Hechler V, Vayer P, Gobaille S, Cash CD, Schmitt M, Bourguignon JJ. A specific gamma-hydroxybutyrate receptor ligand possesses both antagonistic and anticonvulsant properties. ''Journal of Pharmacology and Experimental Therapeutics''. 1990 Nov;255(2):657-63. PMID 2173754</ref><ref>Schmidt C, Gobaille S, Hechler V, Schmitt M, Bourguignon JJ, Maitre M. Anti-sedative and anti-cataleptic properties of NCS-382, a gamma-hydroxybutyrate receptor antagonist. ''European Journal of Pharmacology''. 1991 Oct 22;203(3):393-7. PMID 1773824</ref><ref>Colombo G, Agabio R, Bourguignon J, Fadda F, Lobina C, Maitre M, Reali R, Schmitt M, Gessa GL. Blockade of the discriminative stimulus effects of gamma-hydroxybutyric acid (GHB) by the GHB receptor antagonist NCS-382. ''Physiology and Behaviour''. 1995 Sep;58(3):587-90. PMID 8587968</ref> It has been proposed as a treatment for GHB [[overdose]] in humans, as well as for the endogenous metabolic disorder [[succinic semialdehyde dehydrogenase deficiency]], but has never been developed for clinical use.<ref>Gupta M, Greven R, Jansen EE, Jakobs C, Hogema BM, Froestl W, Snead OC, Bartels H, Grompe M, Gibson KM. Therapeutic intervention in mice deficient for succinate semialdehyde dehydrogenase (gamma-hydroxybutyric aciduria). ''Journal of Pharmacology and Experimental Therapeutics''. 2002 Jul;302(1):180-7. PMID 12065715</ref> | '''NCS-382''' is a moderately selective [[Receptor antagonist|antagonist]] for the [[GHB receptor]].<ref>Castelli MP, Pibiri F, Carboni G, Piras AP. A review of pharmacology of NCS-382, a putative antagonist of gamma-hydroxybutyric acid (GHB) receptor. ''CNS Drug Reviews''. 2004 Fall;10(3):243-60. PMID 15492774</ref> It blocks the effects of [[gamma-Hydroxybutyric acid|GHB]] in animals and has both anti-[[sedative]] and [[anticonvulsant]] effects.<ref>Maitre M, Hechler V, Vayer P, Gobaille S, Cash CD, Schmitt M, Bourguignon JJ. A specific gamma-hydroxybutyrate receptor ligand possesses both antagonistic and anticonvulsant properties. ''Journal of Pharmacology and Experimental Therapeutics''. 1990 Nov;255(2):657-63. PMID 2173754</ref><ref>Schmidt C, Gobaille S, Hechler V, Schmitt M, Bourguignon JJ, Maitre M. Anti-sedative and anti-cataleptic properties of NCS-382, a gamma-hydroxybutyrate receptor antagonist. ''European Journal of Pharmacology''. 1991 Oct 22;203(3):393-7. PMID 1773824</ref><ref>Colombo G, Agabio R, Bourguignon J, Fadda F, Lobina C, Maitre M, Reali R, Schmitt M, Gessa GL. Blockade of the discriminative stimulus effects of gamma-hydroxybutyric acid (GHB) by the GHB receptor antagonist NCS-382. ''Physiology and Behaviour''. 1995 Sep;58(3):587-90. PMID 8587968</ref> It has been proposed as a treatment for GHB [[overdose]] in humans, as well as for the endogenous metabolic disorder [[succinic semialdehyde dehydrogenase deficiency]], but has never been developed for clinical use.<ref>Gupta M, Greven R, Jansen EE, Jakobs C, Hogema BM, Froestl W, Snead OC, Bartels H, Grompe M, Gibson KM. Therapeutic intervention in mice deficient for succinate semialdehyde dehydrogenase (gamma-hydroxybutyric aciduria). ''Journal of Pharmacology and Experimental Therapeutics''. 2002 Jul;302(1):180-7. PMID 12065715</ref> | ||
| Line 33: | Line 33: | ||
== References == | == References == | ||
{{reflist|2}} | |||
[[Category:Carboxylic acids]] | [[Category:Carboxylic acids]] | ||
Latest revision as of 19:56, 4 September 2012
|
WikiDoc Resources for NCS-382 |
|
Articles |
|---|
|
Most recent articles on NCS-382 |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on NCS-382 at Clinical Trials.gov Clinical Trials on NCS-382 at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on NCS-382
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating NCS-382 Risk calculators and risk factors for NCS-382
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for NCS-382 |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
NCS-382 is a moderately selective antagonist for the GHB receptor.[1] It blocks the effects of GHB in animals and has both anti-sedative and anticonvulsant effects.[2][3][4] It has been proposed as a treatment for GHB overdose in humans, as well as for the endogenous metabolic disorder succinic semialdehyde dehydrogenase deficiency, but has never been developed for clinical use.[5]
References
- ↑ Castelli MP, Pibiri F, Carboni G, Piras AP. A review of pharmacology of NCS-382, a putative antagonist of gamma-hydroxybutyric acid (GHB) receptor. CNS Drug Reviews. 2004 Fall;10(3):243-60. PMID 15492774
- ↑ Maitre M, Hechler V, Vayer P, Gobaille S, Cash CD, Schmitt M, Bourguignon JJ. A specific gamma-hydroxybutyrate receptor ligand possesses both antagonistic and anticonvulsant properties. Journal of Pharmacology and Experimental Therapeutics. 1990 Nov;255(2):657-63. PMID 2173754
- ↑ Schmidt C, Gobaille S, Hechler V, Schmitt M, Bourguignon JJ, Maitre M. Anti-sedative and anti-cataleptic properties of NCS-382, a gamma-hydroxybutyrate receptor antagonist. European Journal of Pharmacology. 1991 Oct 22;203(3):393-7. PMID 1773824
- ↑ Colombo G, Agabio R, Bourguignon J, Fadda F, Lobina C, Maitre M, Reali R, Schmitt M, Gessa GL. Blockade of the discriminative stimulus effects of gamma-hydroxybutyric acid (GHB) by the GHB receptor antagonist NCS-382. Physiology and Behaviour. 1995 Sep;58(3):587-90. PMID 8587968
- ↑ Gupta M, Greven R, Jansen EE, Jakobs C, Hogema BM, Froestl W, Snead OC, Bartels H, Grompe M, Gibson KM. Therapeutic intervention in mice deficient for succinate semialdehyde dehydrogenase (gamma-hydroxybutyric aciduria). Journal of Pharmacology and Experimental Therapeutics. 2002 Jul;302(1):180-7. PMID 12065715